Nonetheless, all of the three anti-PD-1 pivotal trials in R/R HL excluded patients with human immunodeficiency virus (HIV) infection and/or with acquired immunodeficiency syndrome (AIDS) due to concerns of worsening retroviral control after manipulation of regulatory elements of the immune system. The gene discussed is PDCD1; the disease is AIDS.